Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVX754 dose-ranging study versus lamivudine in treatment-experienced HIV-1 patients with M184V mutation
ACTRN12605000742673Phase 2Recruiting
- Sponsor
- Avexa Limited
- Start
- Jun 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apricitabine in Human immunodeficiency virus infection type 1 (3 arms), sponsored by Avexa Limited. Started Jun 2005; status: recruiting.
02
Drugs
apricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on ACTRN12605000742673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000742673.